Decision Benefits South Carolina Medicaid Patients with Chronic Wounds

NEWPORT NEWS, Virginia (December 28, 2013) – Effective immediately, the South Carolina Department of Health and Human Services will provide coverage to nearly one million people for the use of TheraSkin®, a real skin therapy that effectively treats chronic wounds such as diabetic foot ulcers and venous leg ulcers.  This decision dovetails with the SC Dept. of Health and Human Services commitment “to bring more accessible and affordable health care services to the people of South Carolina.”

“We applaud the decision by SCDHHS to cover this limb and life-saving product,” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that South Carolina residents with diabetic and venous leg ulcers will now have access to cost-effective living cell therapy.

Patients who have particularly benefited from the wound healing capabilities of TheraSkin are those with diabetes. The percentage of SC residents that suffer from diabetes has increased nearly 20% over just the last several years, to about 12% or 435,000 people. Diabetes costs the State more than $4.5 billion annually.

“Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.

“We will work tirelessly with the medical institutions and practitioners in South Carolina to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, President of Soluble Systems.

TheraSkin is not only clinically effective, but economical, costing 50 – 70% less than competing biologically active products, saving patients and the SC Medicaid program thousands of dollars per treatment. TheraSkin is a potent new weapon in the battle against rising healthcare costs.

TheraSkin is a biologically active, cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing.